approval · primary record
LEVOTHYROXINE SODIUM
2 approval events · latest 2026-10-21
| Agency | FDA |
|---|---|
| Submission type | NDA |
| Latest action | 2026-10-21 |
| Approval events | 2 |
| Brand | LEVOTHYROXINE SODIUM |
| Sponsor | FRESENIUS KABI USA |
| Route | INTRAVENOUS |
Approval history
2 actions on record. The drug is the stable record; each action below is an event with its own date, so this URL keeps working as new actions arrive.
| Date | Agency | Type | Brand | Sponsor | Route |
|---|---|---|---|---|---|
| 2026-10-21 | FDA | NDA | LEVOTHYROXINE SODIUM | FRESENIUS KABI USA | INTRAVENOUS |
| 2026-05-04 | FDA | NDA | LEVO-T | CEDIPROF INC | ORAL |
Provenance
- Source: openFDA Drugs@FDA
- Fetched at: 2026-10-30T00:30:20.737Z
- Licence class: public-domain
- Verdict: primary-source
- Entity id: approval:levothyroxine-sodium
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Levothyroxine Sodium · compound